Published on in Vol 10 (2024)

Preprints (earlier versions) of this paper are available at https://preprints.jmir.org/preprint/49755, first published .
Assessing the Labeling Information on Drugs Associated With Suicide Risk: Systematic Review

Assessing the Labeling Information on Drugs Associated With Suicide Risk: Systematic Review

Assessing the Labeling Information on Drugs Associated With Suicide Risk: Systematic Review

Journals

  1. Xie W, Xiang D, Li Y, Ge M, Deng A. An exploratory study evaluating the 20 medications most commonly associated with suicidal ideation and self-injurious behavior in the FAERS database. BMC Pharmacology and Toxicology 2025;26(1) View
  2. López Carabaño A, Escudero Araus M, Docavo Barrenechea-Moxo J, Bengoechea Aldaz J. Ideación suicida por pregabalina. Caso clínico en atención primaria. Medicina de Familia. SEMERGEN 2025;51(5):102505 View
  3. Deng Y, Shi S, Feng S, Tan X, Wang Y, Yin J, Liu S, Gao Y. Safety of infliximab and adalimumab in pediatric inflammatory bowel diseases: a disproportionality analysis from the FAERS database. BMC Gastroenterology 2025;25(1) View
  4. Annamalah S, Sham R, Foroughi A, Ahmed S. Socio-Economic Drivers of Drug Abuse and Criminal Activities: A Multidimensional Analysis. Deviant Behavior 2025:1 View